AptarGroup, Inc. Q2 2024 10-Q Summary
Business Context and Reporting Period
This summary covers AptarGroup, Inc.'s (ATR) Form 10-Q for the quarterly period ended June 30, 2024. Aptar is a global provider of dispensing, sealing, and protection technologies for the pharmaceutical, beauty, and food/beverage markets. The company operates through three segments: Aptar Pharma, Aptar Beauty, and Aptar Closures.
Key Financial Metrics
| Metric (in millions) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Net Sales | $910.1 | $895.9 | $1,825.5 | $1,756.0 |
| Operating Income | $126.0 | $116.6 | $238.1 | $200.5 |
| Net Income (Attributable to Aptar) | $90.5 | $83.1 | $173.6 | $137.8 |
| Diluted EPS | $1.34 | $1.24 | $2.57 | $2.07 |
| Adjusted EBITDA | $192.8 | $181.2 | $371.6 | $334.9 |
| Operating Margin | 13.8% | 13.0% | 13.0% | 11.4% |
| Free Cash Flow (YTD) | $92.0 | $27.2 | - | - |
| Total Debt | $1,087.3 | - | - | - |
| Cash & Equivalents | $221.5 | - | - | - |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 2% in Q2 and 4% YTD compared to the prior year. Core sales (excluding currency and acquisitions) grew 3% in Q2 and 4% YTD, driven by strong volume growth in prescription drug, consumer healthcare, and personal care applications.
- Profitability Expansion: Operating income rose 8% in Q2 and 19% YTD. Operating margins improved to 13.8% in Q2 (from 13.0%) and 13.0% YTD (from 11.4%), aided by a favorable product mix (higher-margin Pharma sales) and cost management initiatives.
- Cost of Sales: Cost of sales as a percentage of net sales decreased to 62.4% in Q2 (from 64.0%) and 63.0% YTD (from 64.4%), reflecting operational improvements and the absence of one-time ERP implementation costs incurred in the prior year.
- Restructuring: Restructuring costs were $2.3 million in Q2 and $5.8 million YTD, significantly lower than the $13.5 million incurred in the same period of 2023.
- Segment Performance:
- Aptar Pharma: Sales up 6% (Q2) and 10% (YTD); Adjusted EBITDA margin improved to 34.1% (Q2) and 33.3% (YTD).
- Aptar Beauty: Sales down 2% (Q2) and 1% (YTD) due to lower tooling sales and normalizing demand in Europe; Adjusted EBITDA margin improved to 13.9% (Q2).
- Aptar Closures: Sales flat to down 1% (Q2); Adjusted EBITDA margin slightly declined to 15.6% (Q2) due to resin cost pass-through timing.
Guidance, Outlook, and Risks
- Q3 2024 Guidance: Management expects diluted EPS in the range of $1.38 to $1.46, excluding restructuring, investment fair value changes, and acquisition costs. This assumes an effective tax rate of 23.5% to 25.5%.
- Capital Expenditures: Estimated 2024 capex net of government grants is expected to be $280 million to $300 million.
- Dividend: The Board declared a 10% increase in the quarterly dividend to $0.45 per share, payable August 15, 2024.
- Debt Refinancing: On July 2, 2024, the company entered into a new $600 million revolving credit facility (maturing 2029) and a $330 million term loan (maturing 2027) to refinance near-term maturities.
- Risks: Key risks include geopolitical conflicts impacting supply chains and demand, raw material cost volatility (resin, metal), foreign currency fluctuations (strong USD dilutive), and customer demand fluctuations in key markets.
Investor Verification Checklist
- Pharma Segment Drivers: Verify the sustainability of the 16% core sales growth in prescription drugs and the recovery in injectables following the prior year's ERP shutdown.
- Beauty Segment Headwinds: Monitor the normalization of demand in Europe and the impact of lower tooling sales on the Beauty segment's revenue trajectory.
- Cost Pass-Throughs: Assess the timing and effectiveness of passing through lower input costs (resin) in the Closures segment to maintain margins.
- Debt Structure: Review the terms of the new July 2024 credit facilities and the impact of higher interest rates on future interest expense.
- Foreign Currency Impact: Evaluate the sensitivity of future earnings to a strengthening U.S. dollar, which has had a dilutive effect on reported results in 2024.